Bomb Report – Lifestyle
Author:
Immunic, Inc.
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 23, 2026
Immunic to Participate in Scientific and Medical Conferences in April
April 9, 2026
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 1, 2026
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 31, 2026
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 10, 2026
Immunic to Participate in Investor Conferences in March
March 6, 2026